Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
14 studies found for:    baricitinib | Phase 2, 3
Show Display Options
Rank Status Study
1 Recruiting A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Baricitinib;   Drug: Placebo
Phase: Phase 2
Sponsor: Eli Lilly and Company
Study Start: March 2016
Primary Completion: October 2017
2 Active, not recruiting A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)
Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib;   Drug: Placebo
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: October 2014
Primary Completion: November 2016
3 Active, not recruiting A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: Baricitinib;   Drug: Placebo;   Drug: Triamcinolone (Optional)
Phase: Phase 2
Sponsor: Eli Lilly and Company
Study Start: February 2016
Primary Completion: March 2017
4 Recruiting An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib;   Drug: Placebo
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: June 2013
Primary Completion: December 2020
5 Completed A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: baricitinib;   Drug: Placebo
Phase: Phase 2
Sponsor/Collaborators: Eli Lilly and Company;   Incyte Corporation
Study Start: August 2012
Primary Completion: September 2014
6 Completed A Moderate to Severe Rheumatoid Arthritis Study
Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo;   Drug: Baricitinib
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: January 2013
Primary Completion: June 2014
7 Completed A Study in Moderate to Severe Rheumatoid Arthritis Participants
Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo;   Drug: Baricitinib
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: December 2012
Primary Completion: September 2014
8 Completed A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
Conditions: Psoriasis;   Skin Diseases;   Skin Diseases, Papulosquamous
Interventions: Drug: Placebo;   Drug: LY3009104
Phase: Phase 2
Sponsor/Collaborators: Eli Lilly and Company;   Incyte Corporation
Study Start: December 2011
Primary Completion: December 2012
9 Completed A Study in Moderate to Severe Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo;   Drug: Adalimumab;   Drug: Baricitinib
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: October 2012
Primary Completion: March 2015
10 Completed A Study in Participants With Moderate to Severe Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib;   Drug: Methotrexate;   Drug: Placebo;   Drug: Folic Acid
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: November 2012
Primary Completion: February 2015
11 Completed INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs
Condition: Rheumatoid Arthritis
Interventions: Drug: INCB028050;   Drug: Placebo
Phase: Phase 2
Sponsor: Incyte Corporation
Study Start: May 2009
Primary Completion: June 2010
12 Completed A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
Condition: Arthritis, Rheumatoid
Interventions: Drug: LY3009104;   Drug: Placebo
Phase: Phase 2
Sponsor/Collaborators: Eli Lilly and Company;   Incyte Corporation
Study Start: October 2010
Primary Completion: December 2011
13 Recruiting Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: Chronic Graft vs Host Disease;   Chronic Graft-Versus-Host Disease
Intervention: Drug: Baricitinib
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
Study Start: April 2016
Primary Completion: January 2020
14 Completed Oral JAK1/JAK2 Selective Inhibitor Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy
Condition: Arthritis, Rheumatoid
Interventions: Drug: LY3009104;   Drug: Placebo
Phase: Phase 2
Sponsor: Eli Lilly and Company
Study Start: November 2011
Primary Completion: November 2012

Study has passed its completion date and status has not been verified in more than two years.